타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Imfinzi (durvalumab) |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | PD-L1 |
Overview Indication | NSCLC (Stage III consolidation), SCLC, biliary tract, HCC |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m |
Positioning Known limitation | escape detection by the immune system |
MoA Mechanism | Durvalumab inhibits PD-L1 binding to PD-1 and CD80 (B7.1), counteracting tumor immune evasion and enhancing cytotoxic T-lymphocyte activity. |
MoA Biomarker | Unresectable Stage III NSCLC post-cCRT (PACIFIC); PD-L1 in other tumors. |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse |
Toxicology Major finding | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. |
Toxicology CRS | N/A |
Clinical Safety signal | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Imfinzi (durvalumab) |
Overview Company | AstraZeneca |
Overview Modality | ANTIBODY |
Overview Target | PD-L1 |
Overview Indication | NSCLC (Stage III consolidation), SCLC, biliary tract, HCC |
Overview Phase | APPROVED |
Overview Status | APPROVED |
Overview Content status | Curated Core |
Overview Data Confidence | Editorial scope · Curated Core |
Overview Development Signal | Development Signal · Established |
Overview Approval status | FDA approved |
Positioning Key differentiator | novel small molecule A 2A R antagonist which inhibits downstream signaling and increases T cell function as well as a novel m |
Positioning Known limitation | escape detection by the immune system |
MoA Mechanism | Durvalumab inhibits PD-L1 binding to PD-1 and CD80 (B7.1), counteracting tumor immune evasion and enhancing cytotoxic T-lymphocyte activity. |
MoA Biomarker | Unresectable Stage III NSCLC post-cCRT (PACIFIC); PD-L1 in other tumors. |
Toxicology Species | Cynomolgus monkey, Macaque, Mouse |
Toxicology Major finding | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. |
Toxicology CRS | N/A |
Clinical Safety signal | Immune-related AEs consistent with PD-(L)1 class; radiation pneumonitis overlap monitoring in Stage III NSCLC. |
Clinical Program phase | APPROVED |
Clinical Trial activity | No active/completed counts |
추천 비교
추천 비교